High 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 16, 1992, Pages 2191-2196

  Johansson, Jan Erik ^a,b   Adami, Hans Olov ^b   Andersson, Swen Olof ^a   Bergström, Reinhold ^c   Holmberg, Lars ^b   Krusemo, Ulla Brith ^c  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TERMINAL CARE;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMAN; MALE; MORBIDITY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; SWEDEN;

EID: 0026589518     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03480160049033     Document Type: Article

References (27)

1. Johansson J-E, Adami H-O, Andersson S-O, Bergström R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer: a population-based study in 223 untreated patients. Lancet. 1989;1:799-803.
2. Bakke A, Grong K, Höisaetre PÅ. Should we treat localized prostatic cancer? In: Proceedings of the 1985 Finnish Urological Club Meeting, March 1,1985. Printao, Finland: Finnish Urological Club; 1985:58-65.
3. Larsson A, Norlen BJ. Five-year follow-up of patients with localized prostatic carcinoma initially referred for expectant treatment. Scand J Urol Nephrol. 1985;19(suppl 93):30.
4. Adolfsson J, Rönström L, Hedlund PO, Löwhagen T, Carstensen J, Tribukait B. The prognostic value of nodal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. J Urol (Paris). 1990;144:1404-1407.
5. George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988;1:494-497.
6. Handley R, Carr TW, Travis D, Powell PH, Hall RR. Deferred treatment for prostate cancer. Br J Urol. 1988;62:249-253.
7. Madsen PO, Graversen PH, Gasser TC, Corle DK. Treatment of localized prostatic cancer. Radical prostatectomy versus placebo: a 15 year follow-up. Scand J Urol Nephrol. 1988;110:95-100.
8. Muskovitz B, Nitecki S, Levin DR. Cancer of prostate: is there a need for aggressive treatment. Urol Int. 1987;42:49-52.
9. Whitmore WF Jr, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991;67:1091-1096.
10. Union Internationale Contre le Cancer. TNM Classification of Malignant Tumours. 3rd ed. Geneva, Switzerland: International Union Against Cancer; 1978.
11. World Health Organization. International Histological Classification of Tumours: Histological Typing of Prostate Tumours. Geneva, Switzerland: World Health Organization; 1980; No. 22.
12. Schmidt JD, Gibbons RP, Johnson DE, Prout GR, Scott WW, Murphy GP. Chemotherapy of advanced prostatic cancer: evaluation of response parameters. Urology. 1976;7:602-611.
13. Karnofsky DA, Burchenal JH. The clinical of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1946.
14. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958;8:699-710.
15. Ederer F, Axtell IM, Cutler SJ. The relative survival rate: a statistical methodology. Monogr Natl Cancer Inst. 1961;6:101-121.
16. Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977;30:431-443.
17. Cox DR. Regression model and life tables. JR Stat Soc. 1972;B34:187-220.
18. Esposti PL. Cytological malignancy grading of prostatic carcinoma by transrectal aspiration biopsy: a five-year follow-up study of 469 hormone-treated patients. Scand J Urol Nephrol. 1971;5: 199-209.
19. Hostetter AL, Pedersen KV, Gustafsson BL, Månson J-C, Boeryd BRG. Diagnosis and localization of prostate carcinoma by fine-needle aspiration cytology and correlation with histologic whole-organ sections after radical prostatectomy. Am J Clin Pathol. 1990;94:693-697.
20. Gervasi LA, Mata JA, Scardino PT. The prognostic significance of the extent of nodal metastases in prostatic cancer. J Urol. 1989;142:332-336.
21. Corriere JN Jr, Cornog JL, Murphy JJ. Prognosis in patients with carcinoma of the prostate. Cancer. 1970;25:911-918.
22. Hanash KA, Utz DC, Cooke EN, Taylor WF, Titus JL. Carcinoma of the prostate: a 15 year follow-up. J Urol. 1972;107:450-453.
23. Scardino PT. Early detection of prostate cancer. Urol Clin North Am. 1989;16:635-655.
24. Bagshaw MA. Potential for radiotherapy alone in prostatic cancer. Cancer. 1985;55:2079-2085.
25. Gibbons RP, Correa RJ, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol. 1989;141:564-566.
26. Middleton RG, Larsen RH. Selection of patients with stage B prostate cancer for radical prostatectomy. Urol Clin North Am. 1990; 17:779-785.
27. Whitmore WF Jr. Overview: historical and contemporary. Monogr Natl Cancer Inst. 1988;7:7-11.